Serotonin and its receptor agonists stimulate the release of arginine vasopressin (AVP) into peripheral blood under intraventricular injection. To test the hypothesis that brain serotonin can modulate the development of natural osmoregulatory responses, the effect of an increase in endogenous brain serotonin on the response to an intragastric hypo- or hyperosmotic loading was studied in Wistar and AVP-deficient Brattleboro rats. 5-Hydroxytryptophan (5-HTP), the rate-limiting serotonin biosynthesis precursor known to increase the brain level of serotonin, was injected intraperitoneally (5 mg/100 g body weight). The renal functional parameters (glomerular filtration rate [GFR], free water reabsorption, and urine flow rate) were monitored during the 4 h after intragastric infusion of water or a 2% NaCl solution (5% of body weight). Plasma AVP was measured by radioimmunoassay. In Wistar rats, intraperitoneal injection of 5-HTP at the same time as water loading prevented the development of the renal diuretic response: there was no increase in urine flow rate and GFR, and free water reabsorption remained at the high level. In AVP-deficient Brattleboro rats, unlike Wistar rats, 5-HTP treatment was without effect on the renal function parameters. In Wistar rats, injection of 5-HTP at the peak of water diuresis produced an abrogation of the diuretic response to water loading due to the increase in free water reabsorption. Plasma AVP increased from 1.2 ± 0.4 to 4.2 ± 1.6 pg/ml (n = 8 in each group, p < 0.01). Hyperosmotic treatment of Wistar rats with a 2% NaCl solution stimulated AVP secretion compared to baseline (from 3.2 ± 0.1, n = 7 to 5.6 ± 0.9, n = 7, p < 0.01), and the saluretic response developed on the background of high free water reabsorption. When injected concomitantly with NaCl solution, 5-HTP revealed no additive effect on plasma AVP and on free water reabsorption. We conclude that the 5-HTP-caused increase in brain serotonin contributed significantly to the dynamics of changes in the osmoregulatory response to the hypo-osmotic challenge due to stimulation of AVP secretion. 5-HTP had no additive effect on the osmoregulatory response to hyperosmotic loading. Peripherally injected 5-HTP had no effect on the renal function, being absent in AVP-deficient Brattleboro rats.

Keywords:
Serotonin, Vasopressin, 5-Hydroxytryptophan, Osmoregulation, Brattleboro rats
1.
Verney EB: The antidiuretic hormone and the factors which determine its release. Proc Soc Lond 1947;135:27–106.
2.
Leng G, Mason WT, Drzewieski K: The supraoptic nucleus as an osmoreceptor. Neuroendocrinology 1982;34:75–82.
3.
Tyryshkina EM: Hepatic sensory receptors: electrophysiological studies with different types of stimulation; in Shimazu T (ed): Liver Innervation. Eastleigh, Libbey, 1996, pp 363–371.
4.
Chen H, Morris M, Key MP, Chen Y: Rapid neurosecretory and cardiovascular response to osmotic stimulation in conscious mice. Neuroendocrinology 2004;80:225–232.
5.
Ohta M, Kimura T, Ota K, Shoji M, Inoe M, Sato K, Yamamoto T, Funyu T, Mori T, Sahata T, Abe K: Central roles of γ-aminobutiric acid (GABA) glycine and glutamate in vasopressin release and cardiovascular function: GABA, glycine and glutamate release in hypothalamus; in Saito T, Kurokawa K, Yoshida S (eds): Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research. Amsterdam, Elsevier Science, 1995, pp 267–273.
6.
Verbalis JG: Osmotic inhibition of neurohypophysial secretion. Ann NY Acad Sci 1993;689:146–160.
7.
Wade CE, Keil LC, Ramsay DJ: Role of volume and osmolality in the control of plasma vasopressin in dehydrated dogs. Neuroendocrinology 1983;37:349–353.
8.
Bie P: Osmoreceptors, vasopressin and control of renal water excretion. Physiol Rev 1980;60:961–1048.
9.
Bouby N, Fernandes S: Mild dehydration, vasopressin and the kidney: animal and human studies. Eur J Clin Nutr 2003;57:S39–S46.
10.
Falke N: Modulation of oxytocin and vasopressin release at the level of the neurohypophysis. Prog Neurobiol 1991;36:465–484.
11.
Hillhouse EW, Milton NG: Effect of acetylcholine and 5-hydroxytryptamine on the secretion of corticotrophin-releasing factor-41 and arginine vasopressin from the rat hypothalamus in vitro. J Endocrinol 1989;122:713–718.
12.
Kjær A, Knigge U, Jorgensen H, Warberg J: Dehydration-induced vasopressin secretion in humans: involvement of the histaminergic system. Am J Physiol 2000;279:E1305–E1310.
13.
Mueller NK, Di S, Paden CM, Herman JP: Activity-dependent modulation of neurotransmitter innervation to vasopressin neurons of the supraoptic nucleus. Endocrinology 2005;146:348–354.
14.
Wang H, Morris JF: Constitutive nitric oxide synthase in hypothalami of normal and hereditary diabetes insipidus rats and mice: role of nitric oxide in osmotic regulation and its mechanism. Endocrinology 1996;137:1745–1751.
15.
Yamaguchi K, Watanabe K, Yamaya K: Evaluation for roles of nitric oxide generated in the anteroventral third ventricular region in controlling vasopressin secretion and cardiovascular system of conscious rats. Eur J Endocrinol 2000;143:523–533.
16.
Ferris CF, Melloni RH Jr, Koppel G, Perry KW, Fuller RW, Delville Y: Vasopressin/serotonin interactions in the anterior hypothalamus control aggressive behavior in golden hamsters. J Neurosci 1997;17:4331–4340.
17.
Larsen PJ, Hay SA, Vrang N, Mikkelsen JD: Origin of projections from the midbrain raphe nuclei to the hypothalamic paraventricular nucleus in the rat: a combined retrograde and anterograde tracing study. Neuroscience 1996;70:963–988.
18.
De Castro-Silva E, Sarmento C, Nascimento TA, Luz CP, Soares T, Marinho A, Cunha M, Bulcao C, De Oliveira IR, Fregoneze JB: Effect of third ventricle administration of L-694,247, a selective 5-HT1D receptor agonist, on water intake in rats. Pharmacol Biochem Behav 1997;57:749–754.
19.
Spinedi E, Gaillard RC: Stimulation of the hypothalamo-pituitary-adrenocortical axis by the central serotonergic pathway: involvement of endogenous corticotropin-releasing hormone but not vasopressin. J Endocrinol Invest 1991;14:551–557.
20.
Altemus M, Cizza G, Gold PW: Chronic fluoxetine treatment reduces hypothalamic vasopressin secretion in vitro. Brain Res 1992;593:311–313.
21.
Faull CM, Charlton JA, Butler TJ, Baylis PH: The effect of acute pharmacological manipulation of central serotonin neurotransmission on osmoregulated secretion of arginine vasopressin in the rat. J Endocrinol 1993;139:77–87.
22.
Lynn-Bullock CP, Welshhans K, Pallas SL, Katz PS: The effect of oral 5-HTP administration on 5-HTP and 5-HT immunoreactivity in monoaminergic brain regions of rats. J Chem Neuroanat 2004;27:129–138.
23.
Bagdy G, Sved AF, Murphy DL, Szemeredi K: Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists. Eur J Pharmacol 1992;210:285–289.
24.
Galfi M, Radacs M, Juhasz F, Molnar A, Laszlo FA: Serotonin-induced enhancement of vasopressin and oxytocin secretion in rat neurohypophyseal tissue culture. Regul Pept 2005;127:225–231.
25.
Jørgensen H, Riis M, Knigge U, Kjær A, Warberg J: Serotonin receptors involved in vasopressin and oxytocin secretion. J Neuroendocrinol 2003;15:242–249.
26.
Lovino M, Steardo L: Effect of substances influencing brain serotonergic transmission on plasma vasopressin levels in the rat. Eur J Pharmacol 1985;113:99–103.
27.
Marar IE, Amico JA: Vasopressin, oxytocin, corticotrophin-releasing factor, and sodium responses during fluoxetine administration in the rat. Endocrinology 1998;8:13–18.
28.
Chwalbinska-Moneta J: Role of hepatic portal osmoreception in the control of ADH release. Am J Physiol 1979;236:E603–E609.
29.
Adachi A, Niijima A, Jacobs HL: A hepatic osmoreceptor mechanism in the rat: electrophysiological and behavioral studies. Am J Physiol 1976;231:1043–1049.
30.
Haberich FJ, Aziz O, Nowaki PE, Ohm WW: Zur Specifität der Osmoreceptoren in der Leber. Pflugers Arch 1969;313:289–299.
31.
Tyryshkina EM, Ivanova LN, Finkinstein YaD: Participation of the liver receptors in the regulation of ion composition, osmolality and extracellular fluid volume. Pflugers Arch 1981;390:270–277.
32.
Popova NK, Naumenko KS, Maslova LN, Amstislavskaya TG, Melidi NN, Bulygina VV, Ivanova LN: Hypothalamic tryptophan hydroxylase and the hypothalamic-pituitary-adrenocortical response to water deprivation and hydration in vasopressin-deficient and normal rats. Pflugers Arch Eur J Physiol 2002;444:372–377.
33.
Faull CM, Rooke P, Baylis PH: The effect of a highly specific serotonin agonist on osmoregulated vasopressin secretion in healthy man. Clin Endocrinol (Oxf) 1991;35:423–430.
34.
Malidelis YI, Panayotacopoulou MT, Van Heerikhuize JJ, Unmehopa UA, Kontostavaki DP, Swaab DF: Absence of a difference in the neurosecretory activity of supraoptic nucleus vasopressin neurons of neuroleptic-treated schizophrenic patients. Neuroendocrinology 2005;82:63–69.
35.
Marar IE, Mulsant BG, Amico JA: Effect of paroxetine on plasma vasopressin and water load testing in elderly individuals. J Geriatr Psychiatry Neurol 2000;13:212–216.
36.
Loscher W, Pagliusi SR, Muller F: L-5-hydroxytryptophan. Correlation between anticonvulsant effect and increases in levels of 5-hydroxyindoles in plasma and brain. Neuropharmacology 1984;23:1041–1048.
37.
Ternaux JP, Boireau A, Bourgoin S, Hamon M, Hery F, Glowinski J: In vivo release of 5-HT in the lateral ventricle of the rat: effects of 5-hydroxytryptophan and tryptophan. Brain Res 1976;101:533–548.
38.
Liard JF, Dolci W, Valloton MB: Plasma vasopressin level after infusions of hypertonic saline solutions into the renal, portal, carotid, or systemic circulation in conscious dogs. Endocrinology 1984;114:986–991.
39.
Laycock JF: Review: the Brattleboro rat with hereditary hypothalamic diabetes insipidus as an ideal experimental model. Lab Anim 1976;10:261–270.
40.
Valtin H, Edwards BR: GFR and the concentration of urine in the absence of vasopressin. Berliner-Davidson reexplored. Kidney Int 1987;31:634–640.
41.
Montes R, Johnson AK: Efferent mechanisms mediating renal sodium and water excretion induced by centrally administered serotonin. Am J Physiol 1990;259:R1267–R1273.
42.
Gibbs DM, Vale W: Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophyseal portal blood. Brain Res 1983;280:176–179.
43.
Steardo L, Lovino M: Vasopressin release after enhanced serotonergic transmission is not due to activation of the peripheral renin-angiotensin system. Brain Res 1986;382:145–148.
44.
Alexander SPH, Peters JA: The 2000 receptors and its channel nomenclature supplement. TiPS 2000(suppl 11):55–58.
45.
Vincent JD, Legendre P, Poulain D, Arnauld E, Theodosis D: Electrophysiology of vasopressin-secreting cells. Front Horm Res 1985;13:52–68.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.